Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid in Organophosphorus Poisoning
NCT04393103Phase 3Withdrawn
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 3 trial of Intralipid 10% in organophosphate poisoning. Planned start Apr 2024; status: withdrawn.
02
Drugs
Intralipid 10%
03
Conditions
organophosphate poisoning
Beyond the preview
Go deeper on NCT04393103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393103.